I ve Participated in a Research Study. Now What? Oleg Shchelochkov, MD NIH/Venditti Lab
|
|
- Janis Flowers
- 5 years ago
- Views:
Transcription
1 I ve Participated in a Research Study. Now What? Oleg Shchelochkov, MD NIH/Venditti Lab
2 Natural History To understand the onset of ORGANIC ACIDEMIAS, progression and outcomes for each body system Biomarkers Discovery and validation of biomarkers Drugs Partnering to develop new drug targets and new treatments
3 Natural History: A Moving Target and the Unknowns
4 Propionic and Methylmalonic Acidemias Multisystem Disorders METABOLIC INSTABILITY = HIGH MORTALITY Long QT interval Arrhythmias Cardiomyopathy Optic nerve atrophy Intellectual impairment Basal ganglia stroke Hearing loss Hyperammonemia Chronic renal failure Onset Progression Hepatomegaly Fatty liver Osteopenia Bone marrow failure Immunodeficiency Pancreatitis GI dysmotility, G/J tube dependence Outcomes
5 % o f p a tie n ts in a c o h o rt H is to r ic a l C ro s s -S e c tio n a l M o r ta lity R a te s in P r o p io n ic A c id e m ia * * Publications Rousson R et al, 1984 Surtees RA et al, 1992 van der Meer et al, 1996 Essa et al, 1998 Perez-Cerda et al, 2000 Sass et al, 2004 de Baulny et al, 2005 Dionisi-Vici et al, 2006 Touati et al, 2006 Grünert et al, 2012 Pena et al, 2012 Rafique, Y e a r o f p u b lic a tio n * Averaged mortality rate
6 Propionic and Methylmalonic Acidemias Multisystem Disorders METABOLIC INSTABILITY = HIGH MORTALITY Long QT interval Arrhythmias Cardiomyopathy Optic nerve atrophy Intellectual impairment Basal ganglia stroke Hearing loss Hyperammonemia Chronic renal failure Onset Progression Hepatomegaly Fatty liver Osteopenia Bone marrow failure Immunodeficiency Pancreatitis GI dysmotility, G/J tube dependence Outcomes
7 % o f p a tie n ts in a c o h o rt H is to r ic a l C ro s s -S e c tio n a l In te lle c tu a l D is a b ility in P r o p io n ic A c id e m ia Intellectual disability % of Patients Publications IQ<60 100% among neonatal onset patients Surtees RA et al, 1992 IQ<75 60% de Baulny, 2005 IQ not specified % Dionisi-Vici 2006 IQ<70 35% Touati et al 2006 IQ<69 76% Grünert et al 2012 Cognitive deficit 72% Pena et al, 2012 IQ <75 75% Witters et al, Y e a r o f p u b lic a tio n
8 Propionic and Methylmalonic Acidemias Multisystem Disorders METABOLIC INSTABILITY = HIGH MORTALITY Long QT interval Arrhythmias Cardiomyopathy Optic nerve atrophy Intellectual impairment Basal ganglia stroke Hearing loss Hyperammonemia Chronic renal failure Onset Progression Hepatomegaly Fatty liver Osteopenia Bone marrow failure Immunodeficiency Pancreatitis GI dysmotility, G/J tube dependence Outcomes
9
10 The MMA and PA Enrollment (July 2018) CD320, 3 TCII, 2 other, 1 undetermined, 6 cblf, 4 cblx, 4 cblg, 4 cble, 1 CMAMMA, 26 MUT, 78 PCCB, 15 PCCA, 13 cblc, 49 cblb, 11 cbla, 15 The MMA Natural History Protocol (n=204) Pending, 1 The PA Natural History Protocol (n=29)
11 Outside records Pre-admit calls Pre-Admission Clinical Evaluation MMA/PA Team Consults Labs Imaging Nutrition/REE Research Studies Labs/Imaging Biobanking Blood Urine Microbiome Exome/Genome Interim Events Communicatio n with home teams Post-Discharge Follow-up 2-5 Days
12 Propionic and Methylmalonic Acidemias Multisystem Disorders METABOLIC INSTABILITY = HIGH MORTALITY Long QT interval Arrhythmias Cardiomyopathy Optic nerve atrophy Intellectual impairment Basal ganglia stroke Hearing loss Hyperammonemia Chronic renal failure Onset Progression Hepatomegaly Fatty liver Osteopenia Bone marrow failure Immunodeficiency Pancreatitis GI dysmotility, G/J tube dependence Outcomes
13 High Prevalence of Abnormal Height and Body Weight in PA Patients
14 Low daily activity levels (overestimation of the activity factor) Dietary nonadherence Discrepant predicted and actual protein and caloric needs Endocrine abnormalities Frequent hospitalizations and intercurrent infections ( sick day diet ) Short Stature with High BMI Toxic effects of propionaterelated metabolites
15 Z -s c o re W e ig h t, Z -s c o re Growth in PA Patients Slows after Birth 4 P v a lu e = n.s B ir th le n g th z - s c o r e H e ig h t z - s c o r e a t th e tim e o f e x a m - 4 B ir th w e ig h z - s c o r e W e ig h t z - s c o r e a t th e tim e o f e x a m
16 C a lo ric In ta k e, % o f R E E S c h o fie ld E q u a tio n, k c a l/d a y Average Reported Caloric Intake in PA Patients Exceeds Measured REE R e p o r te d C a lo ric In ta k e a s % o f R E E S c h o fie ld E q u a tio n (p r e d ic te d ) R E E, k c a l/d a y R 2 = 0.59 P value =
17 P re s c rib e d c o m p le te p ro te in g m /k g /d a y PA Patients Adhere to the Prescribed Complete Protein R 2 = 0.71 P value = R e p o rte d C o m p le te p ro te in in ta k e g /k g /d a y
18 Prevalence of Endocrine Abnormalities in the PA Cohort Parameter Prevalence Low plasma IGF1 2/19 Blood TSH in the 4-10 mciu/ml range (subclinical hypothyroidism) 7/21* Elevated PTH 3/19** * This number includes 5 patients who had blood TSH in the 4-10 mciu/ml range and two patients had normal TSH, but treated with levothyroxine. A total of 3/21 patients in the NIH PA cohort were treated with levothyroxine. ** 3 patients with elevated PTH accompanying chronic kidney disease
19 H t, z -s c o r e 4 2 P la s m a P r o p io n y lc a r n itin e v s H e ig h t Z -s c o re P v a lu e = R 2 = C 3, P la s m a
20 Growth in Propionic Acidemia Patients Parental Heights G-tube Total Protein Intake Growth Medical Foods The severity of PA mutations Growth Diet Sick day Renal Disease Heart Disease
21 Opportunities for Collaboration Emergency and Acute Care Care under 2 years of Age Newborn Screening and the Initial Presentation
22 Biomarkers
23 Biomarkers and Drug Development Biomarker is any measurable outcome associated with the studied disease No FDA-approved biomarkers - MMA and PA
24 Discovery and Validation of Surrogate Endpoints for Organic Acidemias Residual Enzyme Activity? Healthcare Utilization Propionic and Methylmalonic Acidemias Plasma MC or MMA? Plasma C3? Other Biomarkers? Growth Survival Neurocognitive Development Associations Not cause and effect Surrogate Endpoints (FDA) True Clinical Outcome (FDA)
25 Discovery and Validation of Surrogate Endpoints for Organic Acidemias Residual Enzyme Activity? Healthcare Utilization Propionic and Methylmalonic Acidemias Plasma MC or MMA? Plasma C3? Growth Survival Liver Transplantation Other Biomarkers? Surrogate Endpoints (FDA) Neurocognitive Development True Clinical Outcome (FDA)
26 Discovery and Validation of Surrogate Endpoints for Organic Acidemias Residual Enzyme Activity? Healthcare Utilization Plasma MC or MMA? Growth Propionic and Methylmalonic Acidemias Diet Change Plasma C3? Other Biomarkers? Survival Neurocognitive Development Surrogate Endpoints (FDA) True Clinical Outcome (FDA)
27 Discovery and Validation of Surrogate Endpoints for Organic Acidemias Residual Enzyme Activity? Healthcare Utilization Plasma MC or MMA? Growth Propionic and Methylmalonic Acidemias Development of Drugs Plasma C3? Other Biomarkers? Survival Neurocognitive Development Surrogate Endpoints (FDA) True Clinical Outcome (FDA)
28 Hospital Records MMA-PA Database Patient-Reported Outcomes Quality of Life Scales Intelligence Tools REDCap -based Surveys
29 Discovery and Validation of Surrogate Endpoints ~500 Parameters Collection of Clinical, Laboratory, Biochemical, Genomic and Research Parameters ~300 Parameters Hypothesis-Driven and Agnostic Surveys of Parameters Correlating with Clinically-Relevant Outcomes ~25 Parameters Cross-Over Replication of Identified Correlations in MMA/PA Sets Review of Patients Charts 3 Endpoints Evaluation of Surrogate Endpoints in Mouse Models of MMA/PA 1-2 FDA Acceptance Pathways (IND/NDA Development, Biomarker Qualification, Scientific Consensus Pathways)
30 F S IQ F S IQ F S IQ Evaluation of Biomarkers in the Real-Life Cohort (PA) R e s e a rc h P a r a m e te r # L a b o r a to r y P a r a m e te r # L a b o r a to r y P a r a m e te r # 2 R2=0.58, P value = R2=0.51, P value = R2=0.12, P value = 0.19
31 Frequency Hospital Records MMA-PA Database High ALT or AST in a Cobalamin C Patient? 70 Abnormal Range Intelligence Tools Observation Value
32 Collaborations
33 Acknowledgements Families, Patients, and Referring Teams Venditti Lab Charles P. Venditti, MD, PhD Irini Manoli, MD, PhD Jennifer Sloan, PhD, MA, CGC Carol Van Ryzin, ARNP Susan Ferry, RN Alexandra (Ally) Pass Jack Gagne NIH Clinical Center Jennifer Myles, RD Megan Schoenfeld, RD National Institute of Mental Health Audrey Thurm, PhD Joseph Snow, PhD NIDDK Kong Chen, PhD Brooks Leither Laura Fletcher Jeffrey Kopp, MD CNMC Andrea Gropman, MD NHGRI (The Caregiver Study) Laura Koehly, PhD Dawn Lea, PhD Jennifer Cleary Lena Eskin
34 Questions
Contribution of Nutrients in Complex Inborn Errors of Metabolism: The Case of Methylmalonic Aciduria (MMA)
Contribution of Nutrients in Complex Inborn Errors of Metabolism: The Case of Methylmalonic Aciduria (MMA) Charles P. Venditti, MD, PhD Head, Organic Acid Research Section No conflicts of interest to declare
More informationClinical Management of Organic Acidemias and OAA Natural History Registry. Kim Chapman MD PhD Children s National Rare Disease Institute
Clinical Management of Organic Acidemias and OAA Natural History Registry Kim Chapman MD PhD Children s National Rare Disease Institute Disclosure Nothing to disclose concerning this lecture Organic acid?
More informationSecondary Energy Deficiencies in Organic Acidemias. Kimberly A Chapman MD PhD Children s National July 26, 2014
Secondary Energy Deficiencies in Organic Acidemias Kimberly A Chapman MD PhD Children s National July 26, 2014 2 Goals of this talk Describe the secondary energy deficiencies seen in organic acidemias
More informationIntroduction to Organic Acidemias. Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.
Introduction to Organic Acidemias Hilary Vernon, MD PhD Assistant Professor of Genetic Medicine Johns Hopkins University 7.25.2014 A Brief Historical Overview Garrod, Archibald E. 1902. The Incidence of
More informationCardiac Disease in Organic Acidemias
Cardiac Disease in Organic Acidemias Kathryn Chatfield, MD, PhD Assistant Professor of Pediatrics Division of Cardiology University of Colorado School of Medicine Children s Hospital Colorado Introduction
More informationENERGY DEFICIENCY IN ORGANIC ACIDEMIAS. Kimberly A. Chapman, M.D., Ph.D. Children s National Medical Center
ENERGY DEFICIENCY IN ORGANIC ACIDEMIAS Kimberly A. Chapman, M.D., Ph.D. Children s National Medical Center 1 What is energy? Energy is the money that drives all biological processes Protein (amino acids),
More informationNewborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis)
Newborn Screen & Development Facts about the genetic diseases new since March 2006 (Excluding Cystic Fibrosis) 1) Argininosuccinic acidemia (ASA) a) Incidence: ~1 in 70,000 b) Deficiency in an enzyme of
More informationRe-Purposing Drugs for the Treatment of Polycystic Kidney Disease:
Re-Purposing Drugs for the Treatment of Polycystic Kidney Disease: Partnership with the Polycystic Kidney Disease Foundation PKD Models: pcy and jck Mice, PCK Rat PreClinOmics, Inc. 1 PKDF Goals The Accelerating
More informationMethylmalonic aciduria
Methylmalonic aciduria Introductory information Written by: F. Hörster, S. Kölker & P. Burgard Reviewed & Revised for North America by: S. van Calcar Methylmalonic aciduria MMA 2 Methylmalonic aciduria
More informationDiet, Exercise and Nutrition in Cancer Prevention and Survivorship
Diet, Exercise and Nutrition in Cancer Prevention and Survivorship Jessica Clague DeHart, PhD, MPH Visiting Professor, Department of Medical Oncology, City of Hope Assistant Professor, Claremont Graduate
More informationExosomes and Pancreatic Cancer
Exosomes and Pancreatic Cancer Anirban Maitra, M.B.B.S. Professor of Pathology and Translational Molecular Pathology Sheikh Ahmed Pancreatic Cancer Research Center University of Texas MD Anderson Cancer
More informationGamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells
Gamma-aminobutyric acid (GABA) treatment blocks inflammatory pathways and promotes survival and proliferation of pancreatic beta cells Gérald J. Prud homme, MD, FRCPC Keenan Research Centre for Biomedical
More informationPACES Research Meeting May 12, Boston, MA. Introduction
PACES Research Meeting May 12, 2015 Boston, MA Introduction On Tuesday May 12 before the annual PACES symposium, a research meeting was held. This was sponsored by Johnson and Johnson. This meeting represents
More informationMini-Review. Methylmalonic acidemia: Current status and research priorities. Xiaoyan Zhou, Yazhou Cui, Jinxiang Han*
73 Mini-Review Intractable & Rare Diseases Research. 2018; 7(2):73-78. Methylmalonic acidemia: Current status and research priorities Xiaoyan Zhou, Yazhou Cui, Jinxiang Han* DOI: 10.5582/irdr.2018.01026
More informationFood and Respiratory Allergy in Ghana Insights from population studies among children
Food and Respiratory Allergy in Ghana Insights from population studies among children Abena S. Amoah Parasitology Department, Noguchi Memorial Institute for Medical Research, Accra, Ghana Parasitology
More informationAETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents
Aetna Better Health 2000 Market Street, Suite 850 Philadelphia, PA 19103 AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Growth Hormone and related agents Revised April 2014 Growth
More informationDRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.
Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development Guidance for Industry DRAFT GUIDANCE This guidance
More informationChronic Kidney Disease in an Adult with Propionic Acidemia
JIMD Reports DOI 10.1007/8904_2013_237 CASE REPORT Chronic Kidney Disease in an Adult with Propionic Acidemia H.J. Vernon S. Bagnasco A. Hamosh C.J. Sperati Received: 14 February 2013 /Revised: 23 April
More informationAccelerate Your Research with Conversant Bio
Imagination has given us the steam engine, the telephone, the talkingmachine and the automobile, for these things had to be dreamed of before they became realities. So I believe that dreams... are likely
More informationDiabetes 101 A Medical Assistant Training Module
Diabetes 101 A Medical Assistant Training Module July 2014 Wendy Stricklin RN, BSN Clinical Quality Consultant Michigan Primary Care Association www.mpca.net Objectives Participant will have a basic understanding
More informationSCREENING FOR THYROID DYSFUNCTION U S P S T F R E C O M M E N D A T I O N S T A T E M E N T M A R I A S T U R L A 8 M A Y 2015
SCREENING FOR THYROID DYSFUNCTION U S P S T F R E C O M M E N D A T I O N S T A T E M E N T M A R I A S T U R L A 8 M A Y 2015 BACKGROUND Thyroid dysfunction represents a continuum from asymptomatic biochemical
More informationMyriad Genetics mychoice HRD Update 06/30/2016
Myriad Genetics mychoice HRD Update 06/30/2016 1 Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationNew Initiatives in Nutrition Research at NIH. Paul M. Coates, Ph.D. DC IFT Food Policy Impact 2018
New Initiatives in Nutrition Research at NIH Paul M. Coates, Ph.D. DC IFT Food Policy Impact 2018 National Nutrition Research Roadmap: Organizing Questions 1: How can we better understand and define eating
More informationUrea Cycle Disorders and Hyperammonemia: Diagnosable Treatable Screenable
Urea Cycle Disorders and Hyperammonemia: Diagnosable Treatable Screenable Marshall L. Summar, M.D. Chief, Division of Genetics and Metabolism Children s National Medical Center Washington, DC, USA Disclosure
More informationEarly Supplementation of Human Milk Oligosaccharides Suppresses Spontaneous Autoimmune Diabetes in Non-obese Diabetic Mice Later in Life
Early Supplementation of Human Milk Oligosaccharides Suppresses Spontaneous Autoimmune Diabetes in Non-obese Diabetic Mice Later in Life Ling Xiao Utrecht University, The Netherlands L.XIAO@UU.NL IPC 2016,
More informationCAUSE OF DEATH IN THE GOLDEN RETRIEVER SURVEY RESULTS 2016
CAUSE OF DEATH IN THE GOLDEN RETRIEVER SURVEY RESULTS 2016 This health survey was designed to tell us the frequency of various diseases in our breed, help us learn the life span of Golden Retrievers, and
More informationNewborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD
Newborn screening for additional metabolic diseases using second-tier strategies Juergen G. Okun, PhD 5th EFLM-UEMS European Joint Congress in Laboratory Medicine 10-13 October 2018 in Antalya, Turkey
More informationFor healthcare professionals Methylmalonic Acidurias
www.e-imd.org For healthcare professionals Methylmalonic Acidurias Methylmalonic acidurias (MMAurias) comprise a group of inborn errors of metabolism characterized by an isolated accumulation of methylmalonic
More informationIntegrating Effectiveness and Safety Outcomes in the Assessment of Treatments
Integrating Effectiveness and Safety Outcomes in the Assessment of Treatments Jessica M. Franklin Instructor in Medicine Division of Pharmacoepidemiology & Pharmacoeconomics Brigham and Women s Hospital
More informationNot Your Typical Case of Ketotic Hypoglycemia
Not Your Typical Case of Ketotic Hypoglycemia Linda Steinkrauss, RN, MSN, CPNP Objectives By the end of this session, attendees should be able to: 1. Discuss the difference between idiopathic ketotic hypoglycemia
More informationObjectives. Disclosures
Klinefelter Syndrome: A Near Miss in a Child with Congenital Hypothyroidism Mandi Cafasso, RN, DNP, CPNP Cincinnati Children s Hospital Medical Center April 28, 2017 Minneapolis, MN PENS Conference Objectives
More informationNewborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet
Newborn screening for congenital metabolic diseases Optional out-of-pocket tests Information Sheet Website:www.tipn.org.tw Telephone:(02)85962050 Ext. 401-403 Service line:(02)85962065 Fax:(02)85962067
More informationA practical approach to the E-IMD patient registry (WP4) (Deliverable #6, milestones #5-7)
A practical approach to the E-IMD patient registry (WP4) (Deliverable #6, milestones #5-7) Major aims of the registry (1) To describe the natural history and outcome of OADs and UCDs (2) To describe and
More information2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?
Pharmacy Prior Authorization AETA BETTER HEALTH KETUCK Growth Hormone (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and
More informationExcerpts from: Fluoride in Drinking Water: A Scientific Review of EPA's Standards (National Research Council, 2006)
Excerpts from: Fluoride in Drinking Water: A Scientific Review of EPA's Standards (National Research Council, 2006) Note 1: The page numbers for the following quotes are those shown on the pages of the
More informationGCIG updates PORTEC-3 and PORTEC-4a
GCIG updates PORTEC-3 and PORTEC-4a Lisbon, October 2016 Carien Creutzberg Leiden University Medical Centre, The Netherlands The PORTEC-3 trial High risk Endometrial Cancer R Pelvic RT (48.6 Gy) 686 Pelvic
More informationNDRI Private Donor Program: Accelerating Biomedical Research via Private Donation
1 NDRI Private Donor Program: Accelerating Biomedical Research via Private Donation Jeffrey Thomas Vice President, Strategic Initiatives Honesto Nunez III Private Donor/Rare Disease Manager Webinar Objectives
More informationCan Pediatricians Provide Case-Management and Long-Term Follow-Up Data for their Patients with PCH?
The PCH Project Long Term Follow-Up of Patients with Primary Congenital Hypothyroidism (PCH) by Primary Care Providers Can Pediatricians Provide Case-Management and Long-Term Follow-Up Data for their Patients
More informationTIBSOVO (ivosidenib) oral tablet
TIBSOVO (ivosidenib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationClinical Guidelines for the Hospitalized Adult Patient with Obesity
Clinical Guidelines for the Hospitalized Adult Patient with Obesity 1 Definition of obesity: Obesity is characterized by an excess storage of adipose tissue that is related to an imbalance between energy
More informationMNGenome Sequencing Test Request Form
MNGenome Sequencing Test Request Form Whole Whole Genome Exome Sequencing Note: Clinical Information and Consent Form are required for MNGenome Orders. *Please note if samples are shipping separately as
More informationOverview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy
Overview of Newborn Screening, Potential Uses of Residual Dried Blood Spots, and Protection of Privacy Alan R. Fleischman, M.D. Senior Vice President and Medical Director Chair, Federal Advisory Committee,
More informationAnna & John J. Sie Center for Down Syndrome Affiliates
Anna & John J. Sie Center for Down Syndrome Affiliates Types of Medical Research Bench or basic research: done in a controlled laboratory setting using nonhuman subjects Clinical research: answer questions
More informationSelective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain.
Selective newborn screening of amino acid, fatty acid and organic acid disorders in the Kingdom of Bahrain. Jamal Golbahar PhD Associate Professor of Molecular Medicine, Department of Molecular Medicine,
More informationWHO Growth Grids/ 2012 Risk Changes. Diane Traver Joyce Bryant
WHO Growth Grids/ 2012 Risk Changes Diane Traver Joyce Bryant Overview CDC vs WHO Growth Charts- Why Change? Transition from
More informationNewborn Screening: Blood Spot Disorders
Newborn Screening: Blood Spot Disorders Arizona s Newborn Screening Program Program Overview Panel of Disorders Disorder Descriptions Program Components Hospitals ADHS Lab ADHS Follow-up ADHS Billing Medical
More informationNUCDF. Why is the immune system important? The immune system is composed of organs and cells. July 20, 2013
NF Virtual Conference Presentation Metabolism, Infection and Immunity in Urea Cycle Disorders Peter J. Mc Guire MS, MD Physician-Scientist NATIONAL HUMAN GENOME RESEARCH INSTITUTE U.S. Department of Health
More informationUAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource
PKD Foundation UAB P30 CORE A: The Hepato-Renal Fibrocystic Diseases Translational Resource http://www.arpkdstudies.uab.edu/ Director: Co-Director: Lisa M. Guay-Woodford, MD William E. Grizzle, MD, PhD
More informationWestern Health Specialist Clinics Access & Referral Guidelines
Western Health Specialist Clinics Access & Referral Guidelines Paediatric Medicine Clinics at Western Health: Western Health operates the following Specialist Clinic services for patients who require assessment
More informationChronic Kidney Disease
Chronic Kidney Disease Chronic Kidney Disease (CKD) Guideline (2010) Chronic Kidney Disease CKD: Executive Summary of Recommendations (2010) Executive Summary of Recommendations Below are the major recommendations
More informationEsther Briganti. Fetal And Maternal Health Beyond the Womb: hot topics in endocrinology and pregnancy. Endocrinologist and Clinician Researcher
Fetal And Maternal Health Beyond the Womb: hot topics in endocrinology and pregnancy Esther Briganti Endocrinologist and Clinician Researcher Director, Melbourne Endocrine Associates Associate Professor,
More informationGenomics & Modern Health Care Caring for the Special Children & Adults of Isolated Populations. Propionic Acidemia
Genomics & Modern Health Care Caring for the Special Children & Adults of Isolated Populations Propionic Acidemia D. Holmes Morton MD Pediatrician, Clinic for Special Children Strasburg, Pennsylvania 17579
More informationMalnutrition and nutrition related problems in adults with mitochondrial diseases
Malnutrition and nutrition related problems in adults with mitochondrial diseases ESN 4/18/2012 Heidi Zweers, diëtist UMCN M. Janssen, G. Wanten, B. Smits, B. v. Engelen Mitochondrial diseases prevalence
More informationRequest for Prior Authorization Growth Hormone (Norditropin
Request for Prior Authorization Growth Hormone (Norditropin, Nutropin/AQ ) Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Growth Hormone require a
More informationOriginal Effective Date: 9/10/09
Subject: Oral and Tube Fed Enteral Nutrition Policy Number: MCR-070 *(This MCR replaces and combines MCG-070 & 071) Original Effective Date: 9/10/09 Revision Date(s): 6/29/12, 8/7/14 This MCR is no longer
More informationDiabetes & the Medicare Population: Idaho
Diabetes & the Medicare Population: Introduction to the Report Diabetes has a considerable impact on the nation s healthcare system and on individuals living with the condition. This report is intended
More informationEvaluation of Failure to Thrive in a Young Child: Case Example of Jeff. Andrew Hsi, MD, MPH Family Medicine Pediatric Grand Rounds, 8 August 2012
Evaluation of Failure to Thrive in a Young Child: Case Example of Jeff Andrew Hsi, MD, MPH Family Medicine Pediatric Grand Rounds, 8 August 2012 Objectives for Presentation At the end of this talk; the
More informationThe Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data
National Center on Birth Defects and Developmental Disabilities The Healthcare Cost of Symptomatic Congenital CMV Disease in Privately Insured US Children: Estimates from Administrative Claims Data Scott
More informationE S T A B L I S H I N G N U T R I T I O N I N Y O U R I C U The Need for a Protocol
E S T A B L I S H I N G N U T R I T I O N I N Y O U R I C U The Need for a Protocol Arthur RH van Zanten, MD PhD Gelderse Vallei Hospital, Ede, The Netherlands Learning objectives Develop an evidence based
More informationContemporary Issues in Adolescent Care. Mental Health
Contemporary Issues in Adolescent Care Mental Health Outline of presentation Normal adolescent development Impact of HIV on adolescents Mental Disorders in adolescents Mental disorders in adolescents with
More informationGA-1. Glutaric Aciduria Type 1. TEMPLE Tools Enabling Metabolic Parents LEarning. Information for families after a positive newborn screening
Glutaric Aciduria Type 1 GA-1 Information for families after a positive newborn screening Adapted by the Dietitians Group BIMDG British Inherited Metabolic Diseases Group BASED ON THE ORIGINAL TEMPLE WRITTEN
More informationCertified Clinical Transplant Nurse (CCTN) * Detailed Content Outline
I. PRETRANSPLANTATION CARE 9 11 3 23 A. Evaluate End-Stage Organ Failure 1 1 1 3 1. History and physical assessment 2. Vital signs and / or hemodynamic parameters 3. Lab values 4. Diagnostic tests B. Monitor
More informationMedical Necessity Guidelines: Oral Formula: Massachusetts Products
Medical Necessity Guidelines: Oral Formula: Massachusetts Products Effective: January 1, 2018 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No Prior Authorization
More informationWhat s New in Newborn Screening?
What s New in Newborn Screening? Funded by: Illinois Department of Public Health Information on Newborn Screening Newborn screening in Illinois is administered by the Illinois Department of Public Health.
More informationImproved IPGM: Demonstrating the Value to both Patients and Hospitals
Improved IPGM: Demonstrating the Value to both Patients and Hospitals Osama Hamdy, MD, PhD, FACE Medical Director, Inpatient Diabetes Program Joslin Diabetes Center Harvard Medical School, Boston, MA Cost
More informationFor Your Baby s Health Department of Health
Newborn Screening For Your Baby s Health Department of Health Why is my baby tested? To help make sure your baby will be as healthy as possible. The blood test provides important information about your
More informationHealth and Wellness for all Arizonans. azdhs.gov
To identify newborns with certain, rare disorders and assist families of affected infants so that they receive appropriate and timely treatment to prevent or delay serious medical problems. To identify
More informationProposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia.
Himmelfarb Health Sciences Library, The George Washington University Health Sciences Research Commons Pediatrics Faculty Publications Pediatrics 1-1-2014 Proposed guidelines for the diagnosis and management
More informationNeli Ulrich, MS, PhD Huntsman Cancer Institute, Salt Lake City Using Genetics and Metabolomics to Advance Precision Prevention
Neli Ulrich, MS, PhD Huntsman Cancer Institute, Salt Lake City Using Genetics and Metabolomics to Advance Precision Prevention February 3-5, 2016 Lansdowne Resort, Leesburg, VA Three Highlights Aspirin
More informationInborn Errors of Metabolism. Metabolic Pathway. Digestion and Fasting. How is Expanded Newborn Screening Different? MS/MS. The body is a factory.
Inborn Errors of Metabolism The body is a factory. Inborn errors of metabolism are rare genetic disorders in which the body cannot properly turn food into energy. The disorders are usually caused by defects
More informationPersonalized medecine Biomarker
Patient Disease Diagnosis Risk prediction Personalized medecine Biomarker Targeted therapies Diagnostic Theranostic: Efficay Toxicity Treatment 1 THE CASE FOR PERSONALIZED MEDICINE IS COMPELLING.. Toxicity
More information33 year old male with a history of resected craniopharyngioma (12 years ago) presents after a seizure. Jess Hwang 9/27/12
33 year old male with a history of resected craniopharyngioma (12 years ago) presents after a seizure Jess Hwang 9/27/12 Craniopharyngioma history In 2000, at age 22, he presented with headache and blurry
More informationCOG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Page 1 of 5 COG-ACNS1422: A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA
More informationDysnatremias: All About the Salt? Internal Medicine Resident Lecture 1/12/16 Steve Schinker, MD
Dysnatremias: All About the Salt? Internal Medicine Resident Lecture 1/12/16 Steve Schinker, MD Water or salt? Dysnatremias In general, disorder of water balance, not sodium balance Volume status is tied
More informationClinical Policy: Valganciclovir (Valcyte) Reference Number: CP.CPA.116 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Valcyte) Reference Number: CP.CPA.116 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationPositive Newborn Screens: What do you do next?
Positive Newborn Screens: What do you do next? James B. Gibson, MD, Ph.D. Biochemical Geneticist at Specially for Children Clinical Associate Professor of Pediatrics UTHSCSA Carla R. Scott, MD Pediatric
More informationHA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up
HA Convention 2016 Master course How to Handle Abnormal Newborn Metabolic Screening Results Causes, Management and Follow up Dr. Josephine Chong Clinical Professional Consultant Centre of Inborn Errors
More informationPersonalized Cancer Neoantigen Vaccines
Personalized Cancer Neoantigen Vaccines Turning the Immune System Against Your own Unique Tumour-Specific Antigens 3 rd Annual Advances in Immuno-Oncology Congress London, May 24, 2018 Agnete Fredriksen,
More informationLYNPARZA (olaparib) oral capsule and tablet
LYNPARZA (olaparib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTRY INFORMTION doi:10.1038/nature11808 NT Phen Met ICR Oligo FCCP pmpk tmpk Supplemental figure 1. -. Primary hepatocytes were treated with 250 um Phenformin, 1 mm Metformin 250 um ICR, 100 nm
More informationDysphagia Outcomes for Patients with Feeding Tubes Undergoing Inpatient Rehabilitation: Follow-Up
Dysphagia Outcomes for Patients with Feeding Tubes Undergoing Inpatient Rehabilitation: Follow-Up R. Jordan Stewart, MEd, CCC-SLP, BRS-S Susan Brady, MS, CCC-SLP, BRS-S Cari Manypenny, MS, CCC-SLP Richard
More informationOverall Implementation Strategy/Focus:
Worksheet 1. IMPLEMENTATION STRATEGY Overall Implementation Strategy/Focus: RAND 1 Key Guideline Element 1. Routine primary care screening for overweight and obesity. Gaps in Current Practices (Planning
More informationCompany/Group Name: Business Telephone: Fax: Option 2:
Application Form Please read through the following before completing this application form in BLOCK CAPITALS. You must disclose all material facts. Failure to do so may invalidate the Cover. A material
More informationNutritional Interventions in Primary Mitochondrial Disorders
Nutritional Interventions in Primary Mitochondrial Disorders Carolyn J Ellaway MBBS PhD FRACP CGHGSA Genetic Metabolic Disorders Service Sydney Children s Hospital Network Disciplines of Child and Adolescent
More informationPediatric Endocrine Society and Endocrine Society. Treatment of Primary Congenital Hypothyroidism
Pediatric Endocrine Society and Endocrine Society Treatment of Primary Approved September 2014 Pediatric Endocrine Society 6728 Old McLean Village Drive McLean, VA 22101 (P) 703-556-9222 (F) 703-556-8729
More informationINITIAL AUTHORIZATION FOR ABA/BEHAVIORAL SERVICES
INITIAL AUTHORIZATION FOR ABA/BEHAVIORAL SERVICES Member Name: Member ID#: Date of Birth: Requesting Provider: Phone Number: NPI #: Provider Address: Date of Initial Evaluation: Services Requested: DIAGNOSIS
More informationPEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP. Denise Rokitka, MD, MPH
PEDIATRIC & ADOLESCENT CANCER SURVIVORSHIP Denise Rokitka, MD, MPH Objectives Describe incidence of childhood cancer and survival rates and causes of early mortality. Understand the late effects of cancer
More informationAcademic Insights for Biomarker Priorities and Candidate Pilot Project(s)
Academic Panel Session Academic Insights for Biomarker Priorities and Candidate Pilot Project(s) Moderators: Dr. Chirag Parikh (Yale) Dr. Kumar Sharma (UCSD) Panelists: Dr. Ronald Perrone (Tufts Medical
More informationBeyond the case for NBS in South Africa. Chris Vorster 28/05/2016
Beyond the case for NBS in South Africa Chris Vorster 28/05/2016 The case for NBS in SA Economic justification Cost Utility analysis = Cost/QALY GDP/Capita Immediate implementation (WHO) Political justification
More informationMeasure Information Form
Release Notes: Measure Information Form Version 3.0b **NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE** Measure Set: Heart Failure (HF) Set Measure ID#: HF-1 Measure Information Form Performance
More informationRetrospective Chart Review Triheptanoin in FAOD patients ICIEM Presentation
Retrospective Chart Review Triheptanoin in FAOD patients ICIEM Presentation Jerry Vockley, M.D., Ph.D. Professor of Pediatrics, School of Medicine Professor of Human Genetics, Graduate School of Public
More informationpanel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders
NGS tests panel tests assessing multiple genes at the same time for the diagnosis of one or more related disorders UKGTN website lists 13 laboratories offering a total of 56 panel test UKGTN listed panel
More informationPBCB Prospective Breast Cancer Biobanking
PBCB Prospective Breast Cancer Biobanking Personal monitoring of breast cancer Medicine Biomarkers Patient journey Fatigue Work-life participation Established by Ernst Lien (Bergen) Gunnar Mellgren (Bergen),
More informationObservational Medical Outcomes Partnership
Implications of Health Outcomes of Interest Definitions: Acute Liver Injury Case Study Judy Racoosin, Patrick Ryan on behalf of OMOP Research Team Observational Medical Outcomes Partnership Established
More information[R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE PLANTATIONS DEPARTMENT OF HEALTH. February October October 1992 (E) September 1995
RULES AND REGULATIONS PERTAINING TO THE NEWBORN METABOLIC, ENDOCRINE, AND HEMOGLOBINOPATHY SCREENING PROGRAM AND THE NEWBORN HEARING LOSS SCREENING PROGRAM [R23-13-MET/HRG] STATE OF RHODE ISLAND AND PROVIDENCE
More informationTEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN
TEXAS MEDICAID Clinical Edit Prior Authorization Growth Hormones: HUMATROPE, NUTROPIN AQ, OMNITROPE, SAIZEN STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING Date: Prescriber First & Last Name:
More informationUK Renal Registry 2013 Annual Informatics Meeting
UK Renal Registry 2013 Annual Informatics Meeting UK Renal Data Collection and Information Model Dr Keith Simpson, Medical Advisor UKRR Peter Nicklin, Business Analyst, HSCIC Birmingham, 25 September 2013
More information